Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Antin, Joseph H  [Clear All Filters]
Journal Article
Herrera AF, Chen L, Khajavian S, Chase M, Darrah J, Maloney D, Ho VT, Soiffer RJ, Antin JH, Forman SJ, et al. Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B-cell Lymphoma. Biol Blood Marrow Transplant. 2019.
Wolach O, Stevenson KE, Wadleigh M, DeAngelo DJ, Steensma DP, Ballen KK, Soiffer RJ, Antin JH, Neuberg DS, Ho VT, et al. Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission. Am J Hematol. 2016.
Zaiken MC, Flynn R, Paz KG, Rhee SY, Jin S, Mohamed FA, Saha A, Thangavelu G, Park PMC, Hemming ML, et al. BET-bromodomain and EZH2 inhibitor treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes. Blood. 2022.
Ion D, Stevenson K, Bin Woo S-, Ho VT, Soiffer R, Antin JH, Treister N. Characterization of oral involvement in acute graft-versus-host disease. Biol Blood Marrow Transplant. 2014.
Bejanyan N, Kim S, Hebert KM, Kekre N, Abdel-Azim H, Ahmed I, Aljurf M, Badawy SM, Beitinjaneh A, Boelens JJan, et al. Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. Blood Adv. 2019;3(20):3123-3131.
Arora M, Hemmer MT, Ahn KWoo, Klein JP, Cutler CS, Urbano-Ispizua A, Couriel DR, Alousi AM, Gale RPeter, Inamoto Y, et al. CIBMTR Chronic GVHD Risk Score Predicts Mortality in an Independent Validation Cohort. Biol Blood Marrow Transplant. 2014.
Forcade E, Kim HT, Cutler C, Wang K, Alho AC, Nikiforow S, Ho VT, Koreth J, Armand P, Alyea EP, et al. Circulating T follicular helper cells with increased function during chronic graft-versus-host-disease. Blood. 2016.
Chhabra S, Liu Y, Hemmer MT, Costa L, Pidala JA, Couriel DR, Alousi AM, Majhail NS, Stuart RK, Kim D, et al. Comparative analysis of calcineurin-inhibitor-based methotrexate and mycophenolate mofetil-containing regimens for prevention of Graft-versus-Host Disease after reduced intensity conditioning allogeneic transplantation. Biol Blood Marrow Transplant. 2018.
Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, et al. Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. J Clin Oncol. 2020:JCO1900396.
Koreth J, Kim HT, Nikiforow S, Milford EL, Armand P, Cutler C, Glotzbecker B, Ho VT, Antin JH, Soiffer RJ, et al. Donor Chimerism Early after Reduced-intensity Conditioning Hematopoietic Stem Cell Transplantation Predicts Relapse and Survival. Biol Blood Marrow Transplant. 2014.
Roeker LE, Kim HT, Glotzbecker B, Nageshwar P, Nikiforow S, Koreth J, Armand P, Cutler C, Alyea EP, Antin JH, et al. Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018.
Gooptu M, Kim HT, Howard A, Choi SW, Soiffer RJ, Antin JH, Ritz J, Cutler CS. Effect of sirolimus on immune reconstitution following myeloablative allogeneic stem-cell transplantation: An ancillary analysis of a randomized controlled trial comparing Tacrolimus/Sirolimus with Tacrolimus/Methotrexate (Blood and Marrow Transplant Clin. Biol Blood Marrow Transplant. 2019.
Shapiro RM, Birch GC, Hu G, Cadavid JVergara, Nikiforow S, Baginska J, Ali AK, Tarannum M, Sheffer M, Abdulhamid YZ, et al. Expansion, persistence, and efficacy of donor memory-like NK cells infused for post-transplant relapse. J Clin Invest. 2022.
Gooptu M, Kim HT, Jacobsen ED, Fisher DC, Lacasce AS, Ho VT, Cutler CS, Koreth J, Soiffer RJ, Antin JH, et al. Favorable Outcomes Following Allogeneic Transplantation in Adults with Hemophagocytic Lymphohistiocytosis. Blood Adv. 2022.
Newell LF, DeFor TE, Cutler C, Verneris MR, Blazar BR, Miller JS, Antin JH, Howard A, Wu J, MacMillan ML, et al. Follistatin and Soluble Endoglin Predict 1-year Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplant. Biol Blood Marrow Transplant. 2019.
Ho VT, Kim HT, Brock J, Galinsky I, Daley H, Reynolds CG, Weber A, Pozdnyakova O, Severgnini M, Nikiforow S, et al. GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized double blinded phase 2 trial. Blood Adv. 2021.
Dubovsky JA, Flynn R, Du J, Harrington BK, Zhong Y, Kaffenberger B, Yang C, Towns WH, Lehman A, Johnson AJ, et al. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest. 2014.
El-Jawahri A, Li S, Antin JH, Spitzer TR, Armand PA, Koreth J, Nikiforow S, Ballen KK, Ho VT, Alyea EP, et al. Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in The Modern Years. Biol Blood Marrow Transplant. 2015.
Murase K, Kim HT, Bascug ORGregory, Kawano Y, Ryan J, Matsuoka K-I, Davids MS, Koreth J, Ho VT, Cutler C, et al. Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. Haematologica. 2014.
Hamilton BK, Liu Y, Hemmer MT, Majhail N, Ringdén O, Kim D, Costa L, Stuart R, Alousi A, Pidala JA, et al. Inferior Outcomes with Cyclosporine and Mycophenolate mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019.
Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A, Lukez AP, Avigan D, Bin Chen Y-, McSweeney P, et al. Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016;375(2):143-153.
Eapen M, Logan BR, Appelbaum FR, Antin JH, Anasetti C, Couriel DR, Chen J, Maziarz RT, McCarthy PL, Nakamura R, et al. Long-term Survival after Transplantation of Unrelated Donor Peripheral Blood or Bone Marrow Hematopoietic Cells for Hematologic Malignancy. Biol Blood Marrow Transplant. 2014.
Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin JH, Kapoor N, Pai S-Y, Rowley SD, Kebriaei P, et al. Multicenter study of banked third party virus-specific T-cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013.
Herrera AF, Kim HT, Kong KA, Faham M, Sun H, Sohani AR, Alyea EP, Carlton VE, Bin Chen Y-, Cutler CS, et al. Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma. Br J Haematol. 2016.
Whangbo J, Nikiforow S, Kim HT, Wahl J, Reynolds CG, Rai SChamling, Kim S, Burden AThomas, Alho A, Lacerda JF, et al. A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease. Blood Adv. 2022.

Pages